vs

Side-by-side financial comparison of Linde plc (LIN) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.

OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $8.8M, roughly 1.5× Linde plc). On growth, Linde plc posted the faster year-over-year revenue change (8.2% vs -22.4%). Linde plc produced more free cash flow last quarter ($898.0K vs $-57.1M). Over the past eight quarters, OCULAR THERAPEUTIX, INC's revenue compounded faster (-5.3% CAGR vs -96.7%).

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

LIN vs OCUL — Head-to-Head

Bigger by revenue
OCUL
OCUL
1.5× larger
OCUL
$13.3M
$8.8M
LIN
Growing faster (revenue YoY)
LIN
LIN
+30.7% gap
LIN
8.2%
-22.4%
OCUL
More free cash flow
LIN
LIN
$58.0M more FCF
LIN
$898.0K
$-57.1M
OCUL
Faster 2-yr revenue CAGR
OCUL
OCUL
Annualised
OCUL
-5.3%
-96.7%
LIN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LIN
LIN
OCUL
OCUL
Revenue
$8.8M
$13.3M
Net Profit
$-64.7M
Gross Margin
48.5%
88.0%
Operating Margin
27.8%
-526.5%
Net Margin
-488.0%
Revenue YoY
8.2%
-22.4%
Net Profit YoY
-33.6%
EPS (diluted)
$3.98
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LIN
LIN
OCUL
OCUL
Q1 26
$8.8M
Q4 25
$8.8B
$13.3M
Q3 25
$8.6B
$14.5M
Q2 25
$8.5B
$13.5M
Q1 25
$8.1B
$10.7M
Q4 24
$8.3B
$17.1M
Q3 24
$8.4B
$15.4M
Q2 24
$8.3B
$16.4M
Net Profit
LIN
LIN
OCUL
OCUL
Q1 26
Q4 25
$1.5B
$-64.7M
Q3 25
$1.9B
$-69.4M
Q2 25
$1.8B
$-67.8M
Q1 25
$1.7B
$-64.1M
Q4 24
$1.7B
$-48.4M
Q3 24
$1.6B
$-36.5M
Q2 24
$1.7B
$-43.8M
Gross Margin
LIN
LIN
OCUL
OCUL
Q1 26
48.5%
Q4 25
88.0%
Q3 25
87.8%
Q2 25
85.6%
Q1 25
88.2%
Q4 24
92.8%
Q3 24
89.9%
Q2 24
90.8%
Operating Margin
LIN
LIN
OCUL
OCUL
Q1 26
27.8%
Q4 25
23.0%
-526.5%
Q3 25
27.5%
-472.3%
Q2 25
27.7%
-502.6%
Q1 25
26.9%
-597.5%
Q4 24
27.4%
-296.1%
Q3 24
25.0%
-298.2%
Q2 24
26.4%
-265.1%
Net Margin
LIN
LIN
OCUL
OCUL
Q1 26
Q4 25
17.5%
-488.0%
Q3 25
22.4%
-477.3%
Q2 25
20.8%
-503.9%
Q1 25
20.6%
-598.7%
Q4 24
20.8%
-283.3%
Q3 24
18.5%
-236.6%
Q2 24
20.1%
-266.3%
EPS (diluted)
LIN
LIN
OCUL
OCUL
Q1 26
$3.98
Q4 25
$3.28
$-0.27
Q3 25
$4.09
$-0.38
Q2 25
$3.73
$-0.39
Q1 25
$3.51
$-0.38
Q4 24
$3.61
$-0.25
Q3 24
$3.22
$-0.22
Q2 24
$3.44
$-0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LIN
LIN
OCUL
OCUL
Cash + ST InvestmentsLiquidity on hand
$4.0M
$737.1M
Total DebtLower is stronger
$24.7M
Stockholders' EquityBook value
$40.1M
$654.3M
Total Assets
$86.3M
$808.1M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LIN
LIN
OCUL
OCUL
Q1 26
$4.0M
Q4 25
$5.1B
$737.1M
Q3 25
$4.5B
$344.8M
Q2 25
$4.8B
$391.1M
Q1 25
$5.3B
$349.7M
Q4 24
$4.8B
$392.1M
Q3 24
$5.2B
$427.2M
Q2 24
$4.6B
$459.7M
Total Debt
LIN
LIN
OCUL
OCUL
Q1 26
$24.7M
Q4 25
$20.7B
Q3 25
$18.6B
Q2 25
$19.7B
Q1 25
$17.6B
Q4 24
$15.3B
Q3 24
$17.5B
Q2 24
$16.9B
Stockholders' Equity
LIN
LIN
OCUL
OCUL
Q1 26
$40.1M
Q4 25
$38.2B
$654.3M
Q3 25
$38.6B
$258.2M
Q2 25
$38.5B
$305.9M
Q1 25
$38.0B
$265.9M
Q4 24
$38.1B
$315.3M
Q3 24
$39.2B
$352.0M
Q2 24
$38.2B
$377.7M
Total Assets
LIN
LIN
OCUL
OCUL
Q1 26
$86.3M
Q4 25
$86.8B
$808.1M
Q3 25
$86.0B
$410.9M
Q2 25
$86.1B
$451.3M
Q1 25
$82.7B
$405.9M
Q4 24
$80.1B
$457.9M
Q3 24
$82.5B
$490.4M
Q2 24
$80.2B
$517.1M
Debt / Equity
LIN
LIN
OCUL
OCUL
Q1 26
0.62×
Q4 25
0.54×
Q3 25
0.48×
Q2 25
0.51×
Q1 25
0.46×
Q4 24
0.40×
Q3 24
0.45×
Q2 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LIN
LIN
OCUL
OCUL
Operating Cash FlowLast quarter
$-54.2M
Free Cash FlowOCF − Capex
$898.0K
$-57.1M
FCF MarginFCF / Revenue
10.2%
-430.9%
Capex IntensityCapex / Revenue
21.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.2B
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LIN
LIN
OCUL
OCUL
Q1 26
Q4 25
$3.0B
$-54.2M
Q3 25
$2.9B
$-50.7M
Q2 25
$2.2B
$-55.2M
Q1 25
$2.2B
$-44.7M
Q4 24
$2.8B
$-39.4M
Q3 24
$2.7B
$-36.6M
Q2 24
$1.9B
$-24.8M
Free Cash Flow
LIN
LIN
OCUL
OCUL
Q1 26
$898.0K
Q4 25
$1.6B
$-57.1M
Q3 25
$1.7B
$-56.7M
Q2 25
$954.0M
$-56.5M
Q1 25
$891.0M
$-46.6M
Q4 24
$1.6B
$-39.6M
Q3 24
$1.7B
$-36.6M
Q2 24
$796.0M
$-25.5M
FCF Margin
LIN
LIN
OCUL
OCUL
Q1 26
10.2%
Q4 25
17.9%
-430.9%
Q3 25
19.4%
-390.0%
Q2 25
11.2%
-419.7%
Q1 25
11.0%
-435.6%
Q4 24
18.8%
-232.0%
Q3 24
19.9%
-237.6%
Q2 24
9.6%
-155.4%
Capex Intensity
LIN
LIN
OCUL
OCUL
Q1 26
Q4 25
16.6%
21.4%
Q3 25
14.8%
41.2%
Q2 25
14.8%
9.3%
Q1 25
15.7%
18.1%
Q4 24
15.1%
1.2%
Q3 24
12.8%
0.6%
Q2 24
13.7%
4.5%
Cash Conversion
LIN
LIN
OCUL
OCUL
Q1 26
Q4 25
1.98×
Q3 25
1.53×
Q2 25
1.25×
Q1 25
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons